Filtered By:
Specialty: Respiratory Medicine
Vaccination: Meningitis Vaccine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 84 results found since Jan 2013.

Expert Review on Nonsurgical Management of Parapneumonic Effusion: Advances, Controversies, and New Directions
Semin Respir Crit Care Med. 2023 Aug;44(4):468-476. doi: 10.1055/s-0043-1769095. Epub 2023 Jul 10.ABSTRACTParapneumonic effusion and empyema are rising in incidence worldwide, particularly in association with comorbidities in an aging population. Also driving this change is the widespread uptake of pneumococcal vaccines, leading to the emergence of nonvaccine-type pneumococci and other bacteria. Early treatment with systemic antibiotics is essential but should be guided by local microbial guidelines and antimicrobial resistance patterns due to significant geographical variation. Thoracic ultrasound has emerged as a leading...
Source: Respiratory Care - July 10, 2023 Category: Respiratory Medicine Authors: Deirdre B Fitzgerald Eva Polverino Grant W Waterer Source Type: research

Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
CONCLUSIONS: Overall, PCV13 demonstrated better protection than PPV23 against pneumococcal disease and all-cause respiratory outcomes in the included studies. Where evaluated, sequential PCV13/PPV23 vaccination showed little benefit over PCV13 alone. Results support the use of PCVs to protect against pneumococcal disease and respiratory infections in adults.PMID:36681604 | DOI:10.1016/j.arbres.2022.12.015
Source: Archivos de Bronconeumologia - January 21, 2023 Category: Respiratory Medicine Authors: Eileen M Dunne Catia Cilloniz Claire von Mollendorf Joseph Lewnard Lindsay R Grant Mary P E Slack Luis Jodar Christian Theilacker Bradford D Gessner Source Type: research

Burden of all-cause and organism-specific parapneumonic empyema hospitalization rates prior to the SARS-CoV-2 pandemic in the United States
CONCLUSION: Early declines in all-cause empyema-related hospitalizations observed right after PCV13 introduction among children in 2010 were sustained through 2019, though rates did not decline among adults.PMID:36592639 | DOI:10.1016/j.rmed.2022.107111
Source: Respiratory Care - January 2, 2023 Category: Respiratory Medicine Authors: Andrew D Wiese Carlos G Grijalva Source Type: research

Effectiveness of the pneumococcal polysaccharide and conjugated vaccines in elderly and high-risk populations in preventing invasive pneumococcal disease: A systematic search and review of the literature
Conclusion: The results from this review indicate a reduction of IPD in elderly and high-risk populations vaccinated with PPV23 and PCV13. The protective effect may be lower in elderly individuals >80 years and in individuals with comorbidities. However, the literature is sparse and large-scale prospective studies are needed to evaluate the effectiveness of PPV23 and PCV13 vaccination in adults in protecting against IPD.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Sikjaer, M., Wik, M. S., Stensholt, S. S., Hilberg, O., Lokke, A. Tags: 10.01 - Respiratory infections and bronchiectasis Source Type: research

Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study
This study is registered at ClinicalTrials.gov, NCT04848584, and is ongoing.FINDINGS: Of 65 813 total admissions during the study period, we included 16 994 in our analyses, of which 7435 were due to BA.1, 1056 were due to BA.2, and 8503 were not due to SARS-CoV-2. In adjusted analyses, two-dose vaccine effectiveness was 40% (95% CI 27 to 50) for hospitalisation and 29% (18 to 38) for emergency department admission against BA.1 and 56% (31 to 72) for hospitalisation and 16% (-5 to 33) for emergency department admission against BA.2. Three-dose vaccine effectiveness was 79% (74 to 83) for hospitalisation and 72% (67 to 77) ...
Source: Respiratory Care - October 10, 2022 Category: Respiratory Medicine Authors: Sara Y Tartof Jeff M Slezak Laura Puzniak Vennis Hong Timothy B Frankland Fagen Xie Bradley K Ackerson Srinivas R Valluri Luis Jodar John M McLaughlin Source Type: research

Effectiveness of the 10-valent pneumococcal conjugate vaccine on pediatric pneumonia confirmed by ultrasound: a matched case-control study
CONCLUSIONS: PCV10 was effective at reducing sonographically-confirmed pneumonia in children aged 3-35 months of age when compared to unvaccinated children. VE increased with the threshold used for consolidation size on ultrasound in clinic and community controls alike. This study provides evidence that lung ultrasound is a useful alternative to chest X-ray for case-control studies evaluating the effectiveness of vaccines against pneumonia.PMID:35915495 | DOI:10.1186/s12931-022-02115-5
Source: Respiratory Care - August 1, 2022 Category: Respiratory Medicine Authors: William Checkley Shakir Hossen Eric D McCollum Farhan Pervaiz Catherine H Miele Miguel A Chavez Lawrence H Moulton Nicole Simmons Arunangshu D Roy Nabidul H Chowdhury Salahuddin Ahmed Nazma Begum Abdul Quaiyum Mathuram Santosham Abdullah H Baqui Source Type: research

An Experimental Human Colonization Model with Pneumococcal Serotype 3 has the Potential to be Used for Vaccine Studies
Am J Respir Crit Care Med. 2022 Jul 20. doi: 10.1164/rccm.202207-1342ED. Online ahead of print.NO ABSTRACTPMID:35856830 | DOI:10.1164/rccm.202207-1342ED
Source: American Journal of Respiratory and Critical Care Medicine - July 20, 2022 Category: Respiratory Medicine Authors: Birgitta Henriques-Normark Ana Rita Narciso Source Type: research

Human Infection Challenge with Serotype 3 Pneumococcus
CONCLUSIONS: An SPN3 human challenge model is feasible and safe with comparable carriage rates to an established SPN6B human challenge model. SPN3 carriage may cause mild upper respiratory symptoms. Clinical trial registration available at www. https://www.isrctn.com/, ID: ISRCTN11306486.PMID:35802840 | DOI:10.1164/rccm.202112-2700OC
Source: American Journal of Respiratory and Critical Care Medicine - July 8, 2022 Category: Respiratory Medicine Authors: Ryan E Robinson Elena Mitsi Elissavet Nikolaou Sherin Pojar Tao Chen Jes ús Reiné Tinashe K Nyazika James Court Kelly Davies Madlen Farrar Patricia Gonzalez-Dias Josh Hamilton Helen Hill Lisa Hitchens Ashleigh Howard Angela Hyder-Wright Maia Lesosky Kon Source Type: research